Piper Sandler analyst David Westenberg reiterates an Overweight rating on Natera shares after the ACMG released guidelines recommending 22Q screening, likely a precursor to ACOG guidelines. The analyst tells investors in a research note that Natera is already running micro deletion, so this would be incremental revenue with zero incremental cost.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera: Published study highlights utility of Signatera test
- Natera publishes experience study in twin pregnancies in Prenatal Diagnosis
- Natera price target lowered to $55 from $70 at Credit Suisse
- CareDx, Natera selloffs ahead of CAC meetings overdone, says Raymond James
- Natera price target lowered to $65 from $72 at Baird
